Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Final Primary Results from the Defifrance Registry Study: Effectiveness and Safety of Defibrotide in the Treatment of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation

Mohamad Mohty, MD PhD, Ibrahim Yakoub-Agha, Myriam Labopin, MD, Didier Blaise, MD, Delphine Lebon, MD, Virginie Gandemer, MD PhD, Sébastien Maury, Cecile Renard, Charlotte Jubert, Robert J. Ryan, Virginie Bouvatier, Jean-Hugues Dalle, MD PhD, Regis Peffault De Latour, MD PhD

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-136685

Published: 2020

Journal Articles

Quality-Adjusted Time without Symptoms of Disease and Toxicity (Q-TWiST) Analysis of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed High-Risk/Secondary Acute Myeloid Leukemia (AML)

Jorge E. Cortes, MD, Tara Lin, MD, Geoffrey L Uy, MD, Robert J. Ryan, Stefan Faderl, Jeffrey E. Lancet, MD

Blood (2020) 136 (Supplement 1): 55–56.

https://doi.org/10.1182/blood-2020-136871

Published: 2020

Journal Articles

Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients Enrolled in CPX-351-301, a Randomized Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, High-Risk and/or Secondary AML

Geoffrey L Uy, MD, Laura F. Newell, MD, Tara Lin, MD, Stuart L. Goldberg, Matthew J. Wieduwilt, MD PhD, Robert J. Ryan, Stefan Faderl, Jeffrey E. Lancet, MD

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-136882

Published: 2020

Journal Articles

Treatment Duration, Symptom Resolution, and Survival in Defibrotide-Treated Patients with Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation: Analysis of a Multinational, Prospective, Observational Registry Study

Franco Locatelli, MD PhD, Maura Faraci, Ibrahim Yakoub-Agha, Stephane Girault, Kate Wheeler, Robert J. Ryan, Raj Hanvesakul, Mohamad Mohty, MD PhD

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-136670

Published: 2020

Journal Articles

Genetic Characteristics and Outcomes By Mutation Status in a Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, High-Risk/Secondary Acute Myeloid Leukemia (AML)

R. Coleman Lindsley, MD PhD, Christopher J. Gibson, MD, H. Moses Murdock, BS, Richard M. Stone, MD, Jorge E. Cortes, MD, Geoffrey L. Uy, MD, Tara L. Lin, MD, Ellen K. Ritchie, MD, Thomas Prebet, MD PhD, Robert J. Ryan, MS, Stefan Faderl, MD, Jeffrey E. Lancet, MD

Blood (2019) 134 (Supplement_1): 15.

https://doi.org/10.1182/blood-2019-124500

Published: 2019

Journal Articles

A Multi-Center, Multinational, Prospective Observational Registry Study of Defibrotide in Patients Diagnosed with Severe Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) after Hematopoietic Cell Transplantation (HCT)

Mohamad Mohty, MD PhD, Marta Lisa Battista, Didier Blaise, MD PhD, Elisabetta Calore, MD, Simone Cesaro, Adam Gassas, Natalia Maximova, Katia Perruccio, Cecile Renard, MD, Robert Wynn, Marco Zecca, Myriam Labopin, MD, Raj Hanvesakul, Robert J. Ryan, MS, Fabio Ciceri, MD, Sarah Lawson, MD

Blood (2019) 134 (Supplement_1): 1972.

https://doi.org/10.1182/blood-2019-123529

Published: 2019

Journal Articles

Phase 3 Exploratory Analysis of Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Received Consolidation with CPX-351 Versus Conventional Chemotherapy

Jonathan E. Kolitz, MD, Daniel H. Ryan, MD, Laura F. Newell, MD, Stephen A. Strickland, MD, Donna E. Hogge, MD PhD, Scott R. Solomon, MD, Gary J. Schiller, MD, Robert J. Ryan, MS, Stefan Faderl, MD, Jorge E. Cortes, MD

Blood (2019) 134 (Supplement_1): 3856.

https://doi.org/10.1182/blood-2019-124553

Published: 2019

Journal Articles

Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory Analysis

Daniel H. Ryan, MD, Laura F. Newell, MD, Ellen K. Ritchie, MD, Stephen A. Strickland, MD, Donna E. Hogge, MD PhD, Scott R. Solomon, MD, Richard M. Stone, MD, Gary J. Schiller, MD, Matthew J. Wieduwilt, MD PhD, Robert J. Ryan, MS, Stefan Faderl, MD, Jorge E. Cortes, MD

Blood (2019) 134 (Supplement_1): 3842.

https://doi.org/10.1182/blood-2019-124516

Published: 2019

Journal Articles

Outcomes in Patients with Therapy-Related Acute Myeloid Leukemia (t-AML) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory Analysis

Jeffrey E. Lancet, MD, David A. Rizzieri, MD, Gary J. Schiller, MD, Scott R. Solomon, MD, Laura F. Newell, MD, Harry P. Erba, MD PhD, Robert J. Ryan, MS, Stefan Faderl, MD, Jorge E. Cortes, MD

Blood (2019) 134 (Supplement_1): 1313.

https://doi.org/10.1182/blood-2019-124383

Published: 2019

Journal Articles

Efficacy and Safety of CPX-351 Versus 7+3 in a Phase 3 Exploratory Analysis in Patients with High-Risk/Secondary Acute Myeloid Leukemia (AML) with Prior Hypomethylating Agent Exposure Who Achieved Remission

Tara L. Lin, MD, Daniel H. Ryan, MD, Ellen K. Ritchie, MD, Stephen A. Strickland, MD, Donna E. Hogge, MD PhD, Scott R. Solomon, MD, Jonathan E. Kolitz, MD, Gary J. Schiller, MD, Matthew J. Wieduwilt, MD PhD, Robert J. Ryan, MS, Stefan Faderl, MD, Jorge E. Cortes, MD

Blood (2019) 134 (Supplement_1): 1316.

https://doi.org/10.1182/blood-2019-124552

Published: 2019

Journal Articles

Final Analysis of Day +100 Survival By Prior Hematopoietic Stem Cell Transplant Type from an Expanded Access Study of Defibrotide for Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome

Paul G Richardson, MD, Angela R. Smith, MD MS, Brandon Triplett, MD, Nancy Kernan, MD, Leslie Lehmann, MD, Robert J. Ryan, Robin L. Hume, MS, William Martin Tappe, MD, Stephan A Grupp, MD PhD

Blood (2017) 130 (Supplement 1): 3224.

https://doi.org/10.1182/blood.V130.Suppl_1.3224.3224

Published: 2017

Journal Articles

Adults Receiving Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) after Hematopoietic Stem Cell Transplantation (HSCT): Final Results from the Expanded-Access Program

Paul G Richardson, MD, Joseph H. Antin, MD, Sergio A. Giralt, MD, Robert J. Ryan, Wei Liang, Robin L. Hume, MS, William Martin Tappe, MD, Nancy A. Kernan, MD

Blood (2017) 130 (Supplement 1): 3225.

https://doi.org/10.1182/blood.V130.Suppl_1.3225.3225

Published: 2017

Journal Articles

Rates of Adverse Events per Patient-Year in a Randomized, Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, Treatment-Related Acute Myeloid Leukemia (AML) or AML with Myelodysplasia-Related Changes

Bruno C Medeiros, MD, Jeffrey E. Lancet, MD, Jorge E. Cortes, MD, Laura F. Newell, MD, Tara L. Lin, MD, Ellen K Ritchie, MD, Robert K. Stuart, MD, Stephen A. Strickland, MD MSCI, Donna Hogge, Scott R Solomon, MD, Richard M. Stone, MD, Dale L. Bixby, Jonathan E. Kolitz, MD, Gary J. Schiller, Matthew J. Wieduwilt, Robert J. Ryan, Michael Chiarella, Arthur C Louie, Geoffrey L. Uy, MD

Blood (2017) 130 (Supplement 1): 1366.

https://doi.org/10.1182/blood.V130.Suppl_1.1366.1366

Published: 2017

Journal Articles

Pooled Analysis of Day +100 Survival for Defibrotide-Treated Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) and Ventilator or Dialysis Dependence Following Hematopoietic Stem Cell Transplantation (HSCT)

Paul G Richardson, MD, Angela R. Smith, MD MS, Nancy A. Kernan, MD, Joseph H. Antin, MD, Leslie Lehmann, MD, Robert J. Ryan, Robin L. Hume, MS, William Martin Tappe, MD, Stephan A Grupp, MD PhD

Blood (2017) 130 (Supplement 1): 1946.

https://doi.org/10.1182/blood.V130.Suppl_1.1946.1946

Published: 2017

Journal Articles

Efficacy and Safety of Defibrotide in Pediatric Patients with Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) after Hematopoietic Stem Cell Transplantation (HSCT): Final Results from the Expanded-Access Program

Nancy A. Kernan, MD, Angela R. Smith, MD MS, Brandon Triplett, MD, Leslie Lehmann, MD, Robert J. Ryan, Wei Liang, Robin L. Hume, MS, William Martin Tappe, MD, Stephan A Grupp, MD PhD

Blood (2017) 130 (Supplement 1): 1948.

https://doi.org/10.1182/blood.V130.Suppl_1.1948.1948

Published: 2017

Journal Articles

Cost-Effectiveness of CPX-351 Versus 7+3 Regimen in the Treatment of Treatment-Related Acute Myeloid Leukemia (tAML) or AML with Myelodysplasia-Related Changes (MRC)

Anuraag Kansal, Mark Du, Oscar Herrera-Restrepo, Robert Leipold, Robert J. Ryan, Arthur C. Louie, Karen Chung

Blood (2017) 130 (Supplement 1): 4674.

https://doi.org/10.1182/blood.V130.Suppl_1.4674.4674

Published: 2017

Journal Articles

Treatment of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) Post-Hematopoietic Stem Cell Transplantation (HSCT) in Patients with Neuroblastoma: Final Data from the Defibrotide Expanded-Access Program

Stephan A Grupp, MD PhD, Brandon Triplett, MD, Araz Marachelian, MD, Sonata Jodele, MD, Robert J. Ryan, Robin L. Hume, MS, William Martin Tappe, MD, Paul G Richardson, MD

Blood (2017) 130 (Supplement 1): 4549.

https://doi.org/10.1182/blood.V130.Suppl_1.4549.4549

Published: 2017

Journal Articles

Efficacy and Safety of CPX-351 Versus 7+3 in Older Adults with Secondary Acute Myeloid Leukemia: Combined Subgroup Analysis of Phase 2 and Phase 3 Studies

Blood (2017) 130 (Supplement 1): 2657.

https://doi.org/10.1182/blood.V130.Suppl_1.2657.2657

Published: 2017

NARROW

Final Primary Results from the Defifrance Registry Study: Effectiveness and Safety of Defibrotide in the Treatment of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation

Quality-Adjusted Time without Symptoms of Disease and Toxicity (Q-TWiST) Analysis of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed High-Risk/Secondary Acute Myeloid Leukemia (AML)

Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients Enrolled in CPX-351-301, a Randomized Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, High-Risk and/or Secondary AML

Treatment Duration, Symptom Resolution, and Survival in Defibrotide-Treated Patients with Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation: Analysis of a Multinational, Prospective, Observational Registry Study

Genetic Characteristics and Outcomes By Mutation Status in a Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, High-Risk/Secondary Acute Myeloid Leukemia (AML)

A Multi-Center, Multinational, Prospective Observational Registry Study of Defibrotide in Patients Diagnosed with Severe Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) after Hematopoietic Cell Transplantation (HCT)

Phase 3 Exploratory Analysis of Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Received Consolidation with CPX-351 Versus Conventional Chemotherapy

Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory Analysis

Outcomes in Patients with Therapy-Related Acute Myeloid Leukemia (t-AML) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory Analysis

Efficacy and Safety of CPX-351 Versus 7+3 in a Phase 3 Exploratory Analysis in Patients with High-Risk/Secondary Acute Myeloid Leukemia (AML) with Prior Hypomethylating Agent Exposure Who Achieved Remission

Final Analysis of Day +100 Survival By Prior Hematopoietic Stem Cell Transplant Type from an Expanded Access Study of Defibrotide for Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome

Adults Receiving Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) after Hematopoietic Stem Cell Transplantation (HSCT): Final Results from the Expanded-Access Program

Rates of Adverse Events per Patient-Year in a Randomized, Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, Treatment-Related Acute Myeloid Leukemia (AML) or AML with Myelodysplasia-Related Changes

Pooled Analysis of Day +100 Survival for Defibrotide-Treated Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) and Ventilator or Dialysis Dependence Following Hematopoietic Stem Cell Transplantation (HSCT)

Efficacy and Safety of Defibrotide in Pediatric Patients with Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) after Hematopoietic Stem Cell Transplantation (HSCT): Final Results from the Expanded-Access Program

Cost-Effectiveness of CPX-351 Versus 7+3 Regimen in the Treatment of Treatment-Related Acute Myeloid Leukemia (tAML) or AML with Myelodysplasia-Related Changes (MRC)

Treatment of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) Post-Hematopoietic Stem Cell Transplantation (HSCT) in Patients with Neuroblastoma: Final Data from the Defibrotide Expanded-Access Program

Efficacy and Safety of CPX-351 Versus 7+3 in Older Adults with Secondary Acute Myeloid Leukemia: Combined Subgroup Analysis of Phase 2 and Phase 3 Studies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only